Clinical Trials
Braintumor Website

There are 56 trials:
Facility: Washington University School of Medicine
Displaying 1 - 50
[1 - 50]     [51 - 56]    
NCT Trial Name# of Centers

NCT02523014

  A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas
340

NCT00892177

  Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
308

NCT01814813

  Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
286

NCT02152982

  Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
273

NCT01648348

  Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
242

NCT02490878

  Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
235

NCT02360215

  Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
187

NCT00898079

  Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
167

NCT00919750

  Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
160

NCT00887146

  Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
158

NCT01096368

  Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
150

NCT02179086

  Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
144

NCT01217437

  Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
138

NCT00336024

  Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
131

NCT02667587

  An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
121

NCT01622868

  Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
104

NCT03155620

  Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
87

NCT01602666

  Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
85

NCT01553149

  Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
76

NCT03213704

  Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
64

NCT03233204

  Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
57

NCT02511405

  A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
53

NCT03180268

  Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
44

NCT03213665

  Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
44

NCT01730950

  Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
31

NCT02323880

  Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
21

NCT02780804

  Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
20

NCT02095132

  WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
18

NCT01922076

  WEE1 Inhibitor AZD1775 and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
17

NCT02632370

  5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor
14

NCT02285439

  Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors
12

NCT02357498

  Transsphenoidal Extent of Resection Study
10

NCT01503086

  Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy
9

NCT03034135

  Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
8

NCT02743078

  OptuneĀ® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
8

NCT02589522

  VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors
7

NCT01933815

  Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
7

NCT02215512

  Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases
5

NCT02311582

  MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
2

NCT02372409

  Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
1

NCT02510950

  Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
1

NCT02371031

  FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas
1

NCT02311556

  Response of Brain Metastases After Gamma-Knife Radiosurgery Using Dynamic Susceptibility-weighted Contrast-enhanced Perfusion Magnetic Resonance Imaging
1

NCT01851733

  MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme
1

NCT01999270

  Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors
1

NCT02084134

  Pituitary Steroid Study
1

NCT01907165

  Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide
1

NCT01661400

  Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors
1

NCT01124461

  BIRN (Biomedical Informatics Research Network) Resources Facilitate the Personalization of Malignant Brain Tumor
1

NCT02669914

  MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
1



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites